World Rank (Jul-30-2023)
44
Market Cap (Jul-30-2023)
221.35 Billion USD
World Rank (Dec-25-2022)
40
Market Cap (Dec-25-2022)
210.67 Billion USD
World Rank (Jan-07-2022)
71
Market Cap (Jan-07-2022)
178.120 Billion USD
World Rank (Jan-01-2021)
93
Market Cap (Jan-01-2021)
130.990 Billion USD
Annual Revenue in USD
44,351 Million USD
Annual Net Income in USD
3,288 Million USD
Total Assets in USD
96,483 Million USD
Total Liabilities in USD
59,425 Million USD
Annual Results for Year ending in
Dec-2022 month
Headquarters State / City
Headquarters Country
Headquarters Sub Region
Headquarters Continent
Company Business
Stock Category
Company Rank in Country in 2022
Company Rank in UK in 2022 is 1
Rank in Country (Jan-2021)
Company Rank in UK in 2021 is 4
Rank in Country (Jan-2020)
Rank in UK in 2020 is 4
Number of Employees
83,500
Employee Count as on Date
As on 2022
ISIN Code:
GB0009895292
Chairman
CEO:
Company Website:
Oxford Vaccine Trials again resumed by Astrazeneca
Oxford Vaccine Trials again resumed by Astrazeneca after UK Regulatory Authorities had given permission to go ahead with trials. Post one person undergoing trials had fallen ill, Astrazeneca temporarily paused trials of Oxford Vaccine.
Then again after review, as UK health regulatory authorities had given permission to go ahead with trials, again Oxford Vaccine Trials started.
Russia vaccine and Oxford vaccine are two vaccines related to Covid-19, that are in most advance stages of testing.